Kingsview Wealth Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
Other funds holding BIIB
Kingsview Wealth Management's BIIB Position: Q3 2026 in Review
Kingsview Wealth Management increased its Biogen (BIIB) stake by 59% in Q3 2026, buying an estimated $147K and bringing the position to 1,865 shares worth $421K. The position accounts for 0.01% of the portfolio, ranked #1037.
Kingsview Wealth Management first reported a position in BIIB in Q3 2017 and has held it in 5 quarters since. 1,062 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.
- Kingsview Wealth Management held 1,865 shares of Biogen worth $421K as of Q3 2026.
- Kingsview Wealth Management bought 694 Biogen shares in Q3 2026, an estimated $147K.
- Biogen made up 0.01% of Kingsview Wealth Management's portfolio in Q3 2026, its #1037 holding.
- Kingsview Wealth Management first reported a position in Biogen in Q3 2017 and has held it in 5 quarters since.
- 1,062 funds tracked by Wall St. Rank held Biogen as of Q3 2026.
Based on Kingsview Wealth Management's 13F filing for Q3 2026, filed 13 Nov 2026.